LBA15 Rates of Pathologic Complete Response (pcr) after Datopotamab Deruxtecan (dato) Plus Durvalumab (durva) Treatment Strategy in the Neoadjuvant Setting: Results from the I-SPY 2.2 Trial
Annals of Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined